Summary & Overview
HCPCS G9063: Non-Small Cell Lung Cancer, Stage I Disease Status
HCPCS Level II code G9063 designates a disease-status entry for patients with non-small cell lung cancer whose extent of disease was initially staged as I and who show no evidence of progression, recurrence, or metastasis. The code is specific to use within a Medicare-approved demonstration project and captures a limited clinical designation tied to initial staging prior to any neo-adjuvant therapy. Nationally, this code matters for documenting cancer staging status in demonstration settings and for consistent reporting of early-stage, stable non-small cell lung cancer.
Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical intent, the typical service type and site of service, and contextual information relevant to billing and program-specific use. The publication summarizes benchmarks and policy-relevant considerations where available, clarifies clinical context for coding use, and identifies areas where input data was not provided. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code G9063 documents oncology disease status for non-small cell lung cancer when the extent of disease was initially established as stage I (prior to any neo-adjuvant therapy, if applicable) with no evidence of disease progression, recurrence, or metastases. This code is specified for use in a Medicare-approved demonstration project and denotes a limited disease-status designation for patients meeting the described clinical criteria.
Service type: Oncology disease-status assessment / staging documentation
Typical site of service: Hospital outpatient clinic, oncology clinic, or other ambulatory oncology setting
Clinical & Coding Specifications
Clinical Context
A 65-year-old patient with a confirmed diagnosis of early-stage non-small cell lung cancer (NSCLC) undergoes evaluation as part of a Medicare-approved demonstration project assessing outcomes for patients initially staged as stage I prior to any neoadjuvant therapy. The oncology multidisciplinary team documents the initial extent of disease as stage I based on imaging (CT chest, PET-CT) and tissue diagnosis (biopsy with pathology report). The patient has no clinical, radiographic, or pathologic evidence of disease progression, recurrence, or metastasis at the time of enrollment. The clinical workflow includes: referral to thoracic surgical oncology or medical oncology; review of prior imaging and pathology; documentation of stage I disease in the medical record prior to any neoadjuvant therapy; coding and billing for the demonstration project activity using G9063; and routine follow-up visits with surveillance imaging and oncology assessments. Typical sites of service include outpatient oncology clinics, thoracic surgery clinics, hospital-based outpatient departments, and cancer center ambulatory settings. Typical patient scenario: an otherwise stable adult with a solitary peripheral stage I NSCLC lesion confirmed by biopsy, staged by PET-CT with no nodal or distant metastases, being entered into the demonstration project to document baseline disease status before any systemic or radiation therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |